NeuroEndocrine Cancer Australia (NECA) continues its advocacy to raise awareness of Von Hippel-Lindau (VHL). Thanks to the tireless efforts of VHL patients and NECA, two national news stories have reached a potential audience of tens of millions, highlighting the new treatment available for VHL and the positive impact it is having on the Von Hippel-Lindau (VHL )patients and community.
The availability of this new treatment is exactly why we do what we do—but our work is far from over. There is still much to be done to ensure neuroendocrine cancer patients in Australia receive the same equitable support as other cancer patients. Together, we will keep pushing for change.
Watch the interviews:
